Preferences for COVID-19 Vaccination in People With Chronic Immune-Mediated Inflammatory Diseases
暂无分享,去创建一个
G. Kaplan | N. Bansback | C. Hitchon | G. Hazlewood | D. Mosher | A. Clarke | C. Barber | M. Harrison | I. Colmegna | L. Proulx | S. Bernatsky | D. Richards | T. Wilson | P. Fortin | Megan Thomas | A. Clarke
[1] A. Iagnocco,et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update , 2022, Annals of the Rheumatic Diseases.
[2] E. Bonfá,et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial , 2022, Annals of the Rheumatic Diseases.
[3] J. Bijlsma. EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions , 2022, Annals of the Rheumatic Diseases.
[4] W. Lems,et al. COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases , 2022, The Lancet Rheumatology.
[5] M. Levine,et al. COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey , 2022, The Lancet Rheumatology.
[6] J. Aviña-Zubieta,et al. COVID-19 Vaccination Uptake Among Individuals With Immune-mediated Inflammatory Diseases in Ontario, Canada, Between December 2020 and October 2021: A Population-based Analysis , 2022, The Journal of Rheumatology.
[7] D. Marshall,et al. The Application of Preference Elicitation Methods in Clinical Trial Design to Quantify Trade-Offs: A Scoping Review , 2021, The Patient - Patient-Centered Outcomes Research.
[8] M. Dubinsky,et al. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID , 2021, Inflammatory bowel diseases.
[9] X. Mariette,et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry , 2021, Annals of the Rheumatic Diseases.
[10] G. Kaplan,et al. Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations , 2021, Journal of the Canadian Association of Gastroenterology.
[11] E. Morand,et al. SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study , 2021, Human vaccines & immunotherapeutics.
[12] Andrew T. Kroger,et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3 , 2021, Arthritis & rheumatology.
[13] P. Gaur,et al. COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey , 2021, Rheumatology International.
[14] P. Tugwell,et al. Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases , 2021, The Journal of Rheumatology.
[15] O. Schieir,et al. Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study. , 2021, Rheumatology.
[16] Andrew T. Kroger,et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1 , 2021, Arthritis & Rheumatology.
[17] M. Dubinsky,et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting , 2021, Gut.
[18] A. Bremander,et al. “Mastering a New Life Situation” – Patients’ Preferences of Treatment Outcomes in Early Rheumatoid Arthritis – A Longitudinal Qualitative Study , 2020, Patient preference and adherence.
[19] N. Bansback,et al. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review , 2019, The Journal of Rheumatology.
[20] D. Marshall,et al. Rheum4U: Development and testing of a web-based tool for improving the quality of care for patients with rheumatoid arthritis. , 2019, Clinical and experimental rheumatology.
[21] F Reed Johnson,et al. The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] Danny Campbell,et al. Including Opt-Out Options in Discrete Choice Experiments: Issues to Consider , 2019, The Patient - Patient-Centered Outcomes Research.
[23] G. Hazlewood. Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments. , 2018, Rheumatic diseases clinics of North America.
[24] M. Ferreira,et al. A critical review of methods used to determine the smallest worthwhile effect of interventions for low back pain. , 2012, Journal of clinical epidemiology.
[25] Andrew Lloyd,et al. Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] Deborah Marshall,et al. Conjoint Analysis Applications in Health — How are Studies being Designed and Reported? , 2010, The patient.
[27] Mickael Bech,et al. Effects coding in discrete choice experiments. , 2005, Health economics.
[28] M. Goldman,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Vaccination and Autoimmune Disease: What Is the Evidence? , 2022 .
[29] Deborah Marshall,et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.